Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2967/jnumed.120.249748 http://scihub22266oqcxt.onion/10.2967/jnumed.120.249748 32680924!8679628!32680924     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32680924.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Nucl+Med 2020 ; 61 (12): 1720-1723 Nephropedia Template TP {{tp|p=32680924|t=2020. Oncology-Inspired Treatment Options for COVID-19 |pdf=|usr=}}{{32680924}} gab.com Text Oncology-Inspired Treatment Options for COVID-19 JO: J Nucl Med http://www.kidney.de/pget.php?&tw=1&pmid=32680924 #FOAvip CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods: CR3022 was labeled with (131)I and purified, yielding (131)I-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of (131)I-CR3022 in the presence and absence of CR3022. Results: We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of (131)I-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% +/- 0.14% specific uptake and 0.10% +/- 0.01% specific uptake, respectively; P < 0.0001). Conclusion: Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging. Twit Text FOAVip Oncology-Inspired Treatment Options for COVID-19 ????J Nucl Med http://www.kidney.de/pget.php?&tw=1&pmid=32680924 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32680924 #FOAvip English Wikipedia <ref>{{Cite pmid|32680924}}</ref> Oncology-Inspired Treatment Options for COVID-19 #MMPMID32680924 Pillarsetty N; Carter LM; Lewis JS; Reiner T J Nucl Med 2020[Dec]; 61 (12): 1720-1723 PMID32680924show ga CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods: CR3022 was labeled with (131)I and purified, yielding (131)I-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of (131)I-CR3022 in the presence and absence of CR3022. Results: We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of (131)I-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% +/- 0.14% specific uptake and 0.10% +/- 0.01% specific uptake, respectively; P < 0.0001). Conclusion: Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging. |Antibodies, Monoclonal/chemistry/*therapeutic use[MESH] |COVID-19/metabolism/*radiotherapy[MESH] |Humans[MESH] |Iodine Radioisotopes/therapeutic use[MESH] |Microspheres[MESH]Oncology-Inspired Treatment Options for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing